Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report assessing the UK molecular diagnostic market.
“Warfarin sensitivity (CYP2C9, VKOR1) NA Tests in UK: Assessment of the Molecular Diagnostic Market”, which is available at bit.ly/2HBx9w, reports that this is the most comprehensive European market report on the emergent field of molecular diagnostics from the end user perspective.
The report shows that hospital and private laboratories have been surveyed to collect information on NA tests performed, test volumes and used platforms and reagents. For data reliability and accurate projections at segment level a 3 step methodology has been applied:
Step 1: Identification of the total number of laboratories by secondary research and short telephone interviews with 561 hospitals to verify existence of internal laboratories.
Step 2: 355 laboratories in UK were classified for NAT activity and overall NA test volume.
Step 3: 36 laboratories provided data on NA test volume, kits, platforms and trends. A list of 44 NA tests have been provided to the labs for structured data entry.
Furthermore, the report discusses tests and technologies that are currently available and wishes from the end user perspectives. It covers key platforms of molecular diagnostics, including Polymerase Chain Reaction (PCR), Real Time PCR (RT-PCR), TMA, LCR, NASBA, SDA, HCA, bDNA.
“Warfarin sensitivity (CYP2C9, VKOR1) NA Tests in UK: Assessment of the Molecular Diagnostic Market” is available from Piribo. For more information go to: http://www.piribo.com/
Piribo product ID: DIG00250
